CMND Clearmind Medicine
- 1.3817
- -0.1183-7.89%
Clearmind Medicine News
Clearmind Medicine Advances MEAI-Based Alcohol Substitute Beverage Program
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday's session following weaker-than-expected quarterly results.Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of
Why Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine Inc. (NASDAQ:CMND) shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.What Happened: The agreement
NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers
Market-Moving News for May 7th
CMND: 60% | Clearmind Medicine shares are trading higher after the company signed an exclusive patent licensing agreement with Yissum Research Development Company.HIMS: 18% | Hims & Hers Health share
Clearmind Medicine Shares Are Trading Higher After the Company Signed an Exclusive Patent Licensing Agreement With Yissum Research Development Company.
Clearmind Medicine Shares Are Trading Higher After the Company Signed an Exclusive Patent Licensing Agreement With Yissum Research Development Company.
UPDATE: Agreement Provides Clearmind With Exclusive Global Rights To Further Develop, Manufacture, And Commercialize Innovative Compounds Invented By Professors Rami Yaka, Ahmed Masaewa And Avi Priel From The Hebrew University
UPDATE: Agreement Provides Clearmind With Exclusive Global Rights To Further Develop, Manufacture, And Commercialize Innovative Compounds Invented By Professors Rami Yaka, Ahmed Masaewa And Avi Priel
Clearmind Medicine Signs Exclusive Patent Licensing Agreement With Yissum Research Development Company; Under Agreement, Clearmind Receives Exclusive Rights To Develop, Manufacture, And Commercialize Novel Compounds For Treating PTSD And Other Mental...
Clearmind Medicine Signs Exclusive Patent Licensing Agreement With Yissum Research Development Company; Under Agreement, Clearmind Receives Exclusive Rights To Develop, Manufacture, And Commercialize
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Vancouver, Canada, May 07, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel
Clearmind Medicine Streamlines Reporting Obligations
Clearmind Applies to Cease Being a Reporting Issuer in Canada
Vancouver, Canada, April 30, 2024 -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical- stage biotech company focused on discovery and development of
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of no
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Vancouver, Canada, April 10, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel
Clearmind Medicine CEO Issues Letter to Shareholders
Vancouver, Canada, April 09, 2024 -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE:CWY0) ("Clearmind" or the "company"), a clinical-stage biotech company focused on discovery and development of novel ps
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
SciSparc- Clearmind Collaboration Evolves With New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
Vancouver, Canada, March 27, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-deri
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
Analysis
Price Target
No Data
